ProShare Advisors LLC Increases Holdings in OPKO Health, Inc. (NASDAQ:OPK)

ProShare Advisors LLC increased its position in shares of OPKO Health, Inc. (NASDAQ:OPK) by 49.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 91,730 shares of the biotechnology company’s stock after buying an additional 30,182 shares during the period. ProShare Advisors LLC’s holdings in OPKO Health were worth $135,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. Barclays PLC raised its stake in OPKO Health by 68.7% in the fourth quarter. Barclays PLC now owns 916,368 shares of the biotechnology company’s stock worth $1,347,000 after buying an additional 373,032 shares in the last quarter. Norges Bank purchased a new position in shares of OPKO Health in the 4th quarter valued at $1,657,000. Millennium Management LLC raised its position in shares of OPKO Health by 85.3% in the 4th quarter. Millennium Management LLC now owns 4,588,526 shares of the biotechnology company’s stock worth $6,745,000 after acquiring an additional 2,112,382 shares in the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of OPKO Health by 4.3% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 455,521 shares of the biotechnology company’s stock worth $670,000 after acquiring an additional 18,571 shares in the last quarter. Finally, Wells Fargo & Company MN lifted its stake in shares of OPKO Health by 14.9% during the 4th quarter. Wells Fargo & Company MN now owns 229,262 shares of the biotechnology company’s stock worth $337,000 after purchasing an additional 29,738 shares during the last quarter. Hedge funds and other institutional investors own 64.63% of the company’s stock.

Insiders Place Their Bets

In other news, CEO Phillip Md Et Al Frost purchased 125,000 shares of the stock in a transaction on Thursday, April 10th. The stock was bought at an average price of $1.36 per share, with a total value of $170,000.00. Following the transaction, the chief executive officer now owns 214,001,448 shares in the company, valued at $291,041,969.28. The trade was a 0.06% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last quarter, insiders have purchased 700,000 shares of company stock valued at $1,123,000. Insiders own 49.69% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have issued reports on the company. Barrington Research reiterated an “outperform” rating and issued a $2.25 target price on shares of OPKO Health in a research note on Thursday, May 1st. JPMorgan Chase & Co. started coverage on shares of OPKO Health in a research report on Friday, April 25th. They set a “neutral” rating for the company. HC Wainwright reaffirmed a “buy” rating and issued a $3.00 price objective on shares of OPKO Health in a research report on Monday, April 7th. Finally, Wall Street Zen lowered shares of OPKO Health from a “hold” rating to a “sell” rating in a research note on Monday, May 5th. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $2.75.

OPKO Health Stock Up 1.5%

OPKO Health stock opened at $1.38 on Tuesday. OPKO Health, Inc. has a 1-year low of $1.19 and a 1-year high of $2.04. The business has a fifty day moving average price of $1.41 and a 200-day moving average price of $1.54. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.97 and a quick ratio of 2.69. The stock has a market capitalization of $1.09 billion, a price-to-earnings ratio of -7.26 and a beta of 1.42.

OPKO Health (NASDAQ:OPK) last issued its quarterly earnings results on Wednesday, April 30th. The biotechnology company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.03). OPKO Health had a negative return on equity of 9.76% and a negative net margin of 18.65%. The business had revenue of $149.90 million during the quarter, compared to analyst estimates of $163.13 million. During the same period in the prior year, the business posted ($0.12) EPS. OPKO Health’s revenue was down 13.7% compared to the same quarter last year. Equities research analysts forecast that OPKO Health, Inc. will post -0.25 EPS for the current fiscal year.

OPKO Health Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.